HROW
HarrowBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-22
Current thesis
The primary-source bull case is that Harrow now has a larger ophthalmic commercial platform, 2025 product-sales growth, year-end cash of $72.9 million, and fresh March 2026 financing earmarked partly for launches and development, which could support a stronger 2026-2027 revenue base if mid-2026 launches land well.
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.1.
What can break
Forward visibility is still modest because the current packet lacks fresh trusted-news or analyst-revision confirmation after the annual filing and March financing event.
Momentum
74
Value
57
Sentiment
48
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $43.00 · Bull $58.00 · Bear $30.00
Data freshness
Prices
As of 2026-07-22
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-22 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-05 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-22
Investment thesis
As of 2026-07-22
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $67.75
Why
Momentum74 · Δ7d +21.2
Value57 · Δ7d -0.1
Sentiment48 · Δ7d -6.3
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Value · See fundamentals
Momentum
74
26% active weight
Current posture
7d trendFlat
Δ7d
+21.2
Δ21d
+1.3
Value
57
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.2
Sentiment
48
34% active weight
Current posture
7d trendSoftening
Δ7d
-6.3
Δ21d
-4.5
Why this grade
Composite grade B. Momentum 74.0 / Value 57.2 / Sentiment 48.2
Fundamentals (TTM)As of 2026-07-21
Fundamentals (TTM)
As of 2026-07-21
Market Cap
$1.63B
Beta
0.07
Shares Out
37.28M
P/E (TTM) · Derived
-312.7
P/S (TTM)
8.12
P/FCF (TTM) · Derived
119.30
Rev YoY
-7.6%
EPS YoY
+49.4%
Gross Margin
+74.1%
Op Margin
+8.0%
Net Debt
$179.05M
Current Ratio
2.48
As of 2026-07-22 • Updated nightlySource: Internal modelMethodology